Search

Background: Numerous studies in the medical and surgical literature have discussed the income gap between male and female physicians, but none has adequately accounted for the disparity., Methods: This study was performed to determine whether gender-related billing and coding differences may be related to the income gap. A 10 percent minimum difference was set a priori as statistically significant. A cohort of 1036 candidates' 9-month case lists for the American Board of Plastic Surgery over a 5-year span (2014 to 2018) was evaluated for relationships between surgeon gender and work relative value units, coding information, major and minor cases performed, and work setting. Data were deidentified by the American Board of Plastic Surgery before evaluation. The authors hypothesized that work relative value units, average codes per case, major cases, and minor cases would be at least 10 percent higher for male than for female physicians., Results: Significant differences were found between male and female surgeons in work relative value units billed, work relative value units billed per case, and the numbers of major cases performed. The average total work relative value units for male surgeons was 19.34 percent higher than for female surgeons [3253.2 (95 percent CI, 3090.5 to 3425.8) versus 2624.1 (95 percent CI, 2435.2 to 2829.6)]. Male surgeons performed 14.28 percent more major cases than female surgeons [77.6 percent (95 percent CI, 72.7 to 82.7 percent) versus 90.5 percent (95 percent CI, 86.3 to 94.9 percent); p = 0.0002]., Conclusions: The authors' findings support the hypothesis that billing and coding practices can, in part, account for income differences between male and female plastic surgeons. Potential explanations include practices focusing on larger and more complex operative cases and differences in coding practices., (Copyright © 2022 by the American Society of Plastic Surgeons.)

Background The routine use of angiotensin-converting enzyme inhibitors (ACEI) during palliation of hypoplastic left heart syndrome is controversial. We sought to describe ACEI prescription in the interstage between stage 1 palliation (stage I Norwood procedure) discharge and stage 2 palliation (stage II superior cavopulmonary anastomosis procedure) admission using the NPC-QIC (National Pediatric Cardiology Quality Improvement Collaborative) registry. Methods and Results Analysis of all patients (n=2180) enrolled in NPC-QIC from 2008 to 2016 included preoperative anatomy, risk factors, and echocardiographic data. ACEI were prescribed at stage I Norwood procedure discharge in 38% of patients. ACEI prescription declined from 2011 to 2016 compared with pre-2010 (36.8% versus 45%; P =0.005) with significant variation across centers (range 7-100%; P <0.001) and decreased prescribing rates associated with increased center volume ( P =0.004). There was no difference in interstage mortality ( P =0.662), change in atrioventricular valve regurgitation ( P =0.101), or change in ventricular dysfunction ( P =0.134) between groups. In multivariable analysis of all patients, atrioventricular septal defect (odds ratio [OR], 1.84; 95% CI, 1.28-2.65) or double outlet right ventricle (OR, 1.47; CI, 1.02-2.11), and preoperative mechanical ventilation (OR, 1.37; 95% CI, 1.12-1.68) were associated with increased ACEI prescription. In multivariable analysis of patients with complete echocardiographic data (n=812), ACEI prescription was more common with at least moderate atrioventricular valve regurgitation (OR, 1.88; 95% CI, 1.22-2.31). Conclusions ACEI prescription remains common in the interstage despite limited evidence of benefit. ACEI prescription is associated with preoperative mechanical ventilation, double outlet right ventricle, and atrioventricular valve regurgitation with marked inter-center variation. ACEI prescription is not associated with reduction in mortality, ventricular dysfunction, or atrioventricular valve regurgitation during the interstage.

The global climate problem becomes tractable if CO(2) emissions from coal use are phased out rapidly and emissions from unconventional fossil fuels (e.g., oil shale and tar sands) are prohibited. This paper outlines technology options for phasing out coal emissions in the United States by approximately 2030. We focus on coal for physical and practical reasons and on the U.S. because it is most responsible for accumulated fossil fuel CO(2) in the atmosphere today, specifically targeting electricity production, which is the primary use of coal. While we recognize that coal emissions must be phased out globally, we believe U.S. leadership is essential. A major challenge for reducing U.S. emissions is that coal provides the largest proportion of base load power, i.e., power satisfying minimum electricity demand. Because this demand is relatively constant and coal has a high carbon intensity, utility carbon emissions are largely due to coal. The current U.S. electric grid incorporates little renewable power, most of which is not base load power. However, this can readily be changed within the next 2-3 decades. Eliminating coal emissions also requires improved efficiency, a "smart grid", additional energy storage, and advanced nuclear power. Any further coal usage must be accompanied by carbon capture and storage (CCS). We suggest that near-term emphasis should be on efficiency measures and substitution of coal-fired power by renewables and third-generation nuclear plants, since these technologies have been successfully demonstrated at the relevant (commercial) scale. Beyond 2030, these measures can be supplemented by CCS at power plants and, as needed, successfully demonstrated fourth-generation reactors. We conclude that U.S. coal emissions could be phased out by 2030 using existing technologies or ones that could be commercially competitive with coal within about a decade. Elimination of fossil fuel subsidies and a substantial rising price on carbon emissions are the root requirements for a clean, emissions-free future.

We hypothesized that the longitudinal changes in peak oxygen uptake, ventilatory efficiency, and exercise-induced right-to-left shunting in patients with pulmonary arterial hypertension (PAH) would predict outcomes better than baseline measurements alone. Patients with PAH die prematurely. Identifying prognostic markers is critical for treating patients with PAH; however, longitudinal prognostic information of PAH is limited. We enrolled 103 patients with PAH into a long-term, prospective outcome study using serial cardiopulmonary exercise testing to measure the peak oxygen uptake, ventilatory efficiency (ratio of ventilation to carbon dioxide output at the anaerobic threshold), right-to-left shunting, and other factors in patients treated with optimal therapy. The patients were followed up for a mean of 4.7 years. During the study period, 20 patients died, and 3 underwent lung transplantation. The baseline peak oxygen uptake and ventilatory efficiency was 0.79 L/min and 49 (normal <34), respectively, reflecting severe disease. Poorer ventilatory efficiency and greater New York Heart Association classification were associated with poor outcome at baseline and at follow-up. On multivariate analysis, the persistence or development of an exercise-induced right-to-left shunt strongly predicted death or transplantation (p <0.0001), independent of the hemodynamics and all other exercise measures, including peak oxygen uptake and ventilatory efficiency. The absence of a shunt at baseline was associated with a 20% rate of nonsurvival, which decreased to 7% at follow-up. A poorer ventilatory efficiency appeared to be associated with a poor outcome in patients without a shunt. In conclusion, a persistent exercise-induced right-to-left shunt and poor ventilatory efficiency were highly predictive of poor outcomes in patients with pulmonary arterial hypertension., (Copyright 2010 Elsevier Inc. All rights reserved.)

Background: Integrated plastic surgery residency training is growing in popularity, bringing new challenges to program directors and applicants. The purpose of this study was to identify characteristics of successful applicants and to obtain feedback from applicants to improve the integrated plastic surgery residency training application and interview process., Methods: An anonymous survey assessing applicant academic qualifications, number of interviews offered and attended, and opinions about the application and interview process was distributed electronically to the 2006 integrated plastic surgery residency training applicant class. The number of interviews offered was used as an indicator of potential applicant success., Results: A 38 percent survey participation rate (139 of 367) was achieved. United States Medical Licensing Examination Step 1 score correlated with number of interview invitations (p < or = 0.001). Successful Alpha Omega Alpha designation (p < or = 0.001), high class rank (p = 0.034), presence of a plastic surgery residency program at the participant's school (p = 0.026), and authorship of one or more publications (p < or = 0.001) were associated with receiving greater number of interview invitations. Geographic location was an important consideration for applicants when applying to and ranking programs. Applicants desired interviews on weekdays and geographic coordination of interviews., Conclusions: Integrated plastic surgery residency training is highly competitive, with the number of interview invitations correlating with academic performance and, to a lesser extent, research. Applicant feedback from this survey can be used to improve the application and interview process.

Objective: To assess the impact of vision loss severity on costs and health outcomes among Medicare beneficiaries with glaucoma., Methods: A retrospective cohort analysis was conducted using Medicare claims. Patients were stratified into 4 categories: no vision loss, moderate vision loss, severe vision loss, and blindness. Outcomes of interest were mean annual medical costs by category, component costs, and frequency of depression, falls and/or accidents, injury, femur fracture, and nursing home placement., Results: Multivariate regression analysis showed that patients with any degree of vision loss had 46.7% higher total costs compared with patients without vision loss. Mean total and component costs increased with onset and severity ($8157 for no vision loss to $18,670 for blindness). Patients with vision loss were significantly more likely to be placed in a nursing home (odds ratio = 2.18; 95% confidence interval, 2.06-2.31), develop depression (odds ratio = 1.63; 95% confidence interval, 1.54-1.73), fracture a femur (odds ratio = 1.67; 95% confidence interval, 1.53-2.83), or experience a fall or accident (odds ratio = 1.59; 95% confidence interval, 1.50-1.68) vs patients without vision loss., Conclusions: Vision loss in glaucoma is costly, and costs increase with severity. There is significantly increased risk of nursing home admission, depression, falls and/or accidents, injury, or femur fracture with vision loss compared with no vision loss.

Background: Current authoritative spirometry guidelines use conflicting percentage of FEV1/FVC ratios (FEV1/FVC%) to define airway obstruction. The American Thoracic Society/European Respiratory Society Task Force characterizes obstruction as a FEV1/FVC% below the statistically defined fifth percentile of normal. However, many recent publications continue to use the Global Initiative for Chronic Obstructive Lung Disease (GOLD) primary criterion that defines obstruction as a FEV1/FVC% < 70%. Data from the Third National Health and Nutrition Examination Survey (NHANES-III) should identify and quantify differences, help resolve this conflict, and reduce inappropriate medical and public health decisions resulting from misidentification., Methods: Using these two guidelines, individual values of FEV1/FVC% were compared by decades in 5,906 healthy never-smoking adults and 3,497 current-smokers of black (African American), Hispanic (Latin), or white ethnicities aged 20.0 to 79.9 years., Results: In the never-smoking population, the lower limits of normal used in other reference equations fit reasonably well the NHANES-III statistically defined fifth percentile guidelines. But nearly one half of young adults with FEV1/FVC% below the NHANES-III fifth percentile of normal were misidentified as normal because their FEV1/FVC% was > 70% (abnormals misidentified as normal). Approximately one fifth of older adults with observed FEV1/FVC% above the NHANES-III fifth percentile had FEV1/FVC% ratios < 70% (normals misidentified as abnormal)., Conclusions: The GOLD guidelines misidentify nearly one half of abnormal younger adults as normal and misidentify approximately one fifth of normal older adults as abnormal.

Study Objectives: To ascertain the degree of dissimilarities among blood gas and pH analyzer models of the same and different manufacturers in measurement of PO2, PCO2, and pH using fluorocarbon containing emulsion (FCE) proficiency testing material., Design: Statistically and graphically analyze data from six recent proficiency testing surveys for the 20 more frequently used models of analyzers., Setting and Participants: Over a 2-year period, approximately 900 participants from blood gas laboratories in the United States analyzed similar ampules from each of 30 lots., Measurements and Results: Both graphic and statistical comparisons were used to demonstrate differences between manufacturers. For each of the four major manufacturers, comparisons revealed statistically significant differences not only for PO2, but also for PCO2 and pH. Additionally, comparison models within each of the three manufacturers (those with multiple models and > 15 instruments per model represented) disclosed statistically significant dissimilarities among models for each analyte in 115 of 153 model pairings. Previously reported tonometered blood differences among analyzer models for PO2 are qualitatively similar to the differences found in these same models in this FCE study. Model differences are important in research studies and may be clinically important in deciding abnormality, selecting oxygen therapy, or the treatment of patients with respiratory failure or severe respiratory alkalosis., Conclusions: To minimize the likelihood of misleading clinicians, laboratory directors should consider the degree of dissimilarity among blood gas analyzer models in current use and when changing instrumentation.